Health Care • Biotechnology: Pharmaceutical Preparations
$6.41 ▼ -0.68
(-9.59%)
MKT CAP: $714.8M • VOL: 185.3K
52W L $5 52W H $9
GYRE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $116.6M | $105.8M | $113.5M |
| YoY Revenue Growth % | +10.2% | -6.8% | — |
| Gross Profit | $111.2M | $101.9M | — |
| Gross Margin % | 95.4% | 96.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $11.5M | $16.2M | -$67.2M |
| Operating Margin % | 9.9% | 15.3% | -59.3% |
| Net Income (GAAP) | $9.9M | $17.9M | -$85.5M |
| EBITDA (Normalized) | $12.4M | $18.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.0M | -$3.6M | $25.9M |
| Capital Expenditures (CapEx) | $1.2M | $2.3M | — |
| Free Cash Flow (FCF) | -$180.0K | -$6.0M | $25.9M |
| FCF Margin % | -0.2% | -5.6% | 22.8% |
| Return on Invested Capital (ROIC %) | 68.2% | 24.8% | — |
| Cash & Short-Term Equivalents | $49.2M | $11.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $62.5M | $63.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GYRE.